Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841715 | 0.85 | DGAT2 (0.32) | L3MBTL1DGAT2PDE2APDE10APTGS2 | |
| SCHEMBL4841759 | 0.80 | PTGS2 (0.34) | L3MBTL1DGAT2MEN1KMT2APDE2A | |
| SCHEMBL4841726 | 0.78 | DGAT2 (0.36) | L3MBTL1DGAT2PTGS2LMNA | |
| SCHEMBL4842636 | 0.78 | DGAT2 (0.33) | L3MBTL1DGAT2PDE2APDE10APTGS2 | |
| SCHEMBL4833086 | 0.77 | SCN9A (0.34) | DGAT2PDE2APDE10ASCN9ALMNA | |
| SCHEMBL4837740 | 0.77 | SCN9A (0.36) | DGAT2PDE2APDE10ASCN9ALMNA | |
| SCHEMBL14018946 | 0.77 | SCN9A (0.34) | DGAT2PDE2APDE10ASCN9ALMNA | |
| SCHEMBL13764811 | 0.72 | MAPK14 (0.45) | PTGS2SCN9AMAPK14 | |
| SCHEMBL4833043 | 0.71 | MAPK14 (0.48) | PTGS2SCN9AMAPK14 | |
| SCHEMBL4839507 | 0.71 | MAPK14 (0.49) | PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | claimed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | L3MBTL1 3443/4885DGAT2 4662/4885MEN1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.